CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...9899100101102103104105106107108...39323933»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal:  Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature. (Pubmed Central) -  Jul 15, 2024   
    A 41-year-old, Gravida 4 Para 3 (3013) with a diagnosis of GTN, Stage III: WHO risk score of 13 (Choriocarcinoma) was initially managed with 10 cycles of multiple agent Etoposide, Methotrexate, Actinomycin D-Cyclophosphomide and Vincristine (EMACO) and 19 cycles of Etoposide, Cisplatin-Etoposide Methotrexate and Actinomycin D (EP-EMA)...She was started on third-line salvage chemotherapy of Paclitaxel and Carboplatin (PC) with concomitant whole brain irradiation completing three cycles after which chemoresistance was again diagnosed with increasing hCG titers and increase in the number and size of the pulmonary masses which were deemed unresectable. Immunotherapy was started with Pembrolizumab showing a good response with marked fall in
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Palbociclib-Induced Vitiligo-Like Lesions: A Report of a Challenging Case. (Pubmed Central) -  Jul 15, 2024   
    This case emphasizes the importance of recognizing rare dermatologic side effects of CDK4/6 inhibitors like palbociclib. Ongoing vigilance, reporting, and research are necessary to improve understanding and management of these side effects, ultimately enhancing patient care in oncology.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Enhancing Success in the ABO-Incompatible Kidney Transplantation: A Case Report. (Pubmed Central) -  Jul 15, 2024   
    Ongoing vigilance, reporting, and research are necessary to improve understanding and management of these side effects, ultimately enhancing patient care in oncology. We present a case report of a 51-year-old male with ESRD secondary to diabetic kidney disease who underwent desensitization for ABOi KT, involving rituximab administration followed by IA using Glycosorb
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    Journal:  A Curious Case of Diabetic Ketoacidosis Secondary to Avelumab. (Pubmed Central) -  Jul 15, 2024   
    At present, the patient has an overall survival of 24 months and shows no evidence of disease with a good quality of life 16 months after avelumab suspension. We hypothesized that a late response to avelumab could explain this unexpected outcome.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  An Aggressive Case of Cryoglobulinemia and Membranoproliferative Glomerulonephritis: A Case Report. (Pubmed Central) -  Jul 15, 2024   
    The treatment involved steroids and rituximab...Pulmonary manifestations are rare and were evident in this case (although without clear evidence of diffuse alveolar hemorrhage) and led to a complicated disease course and an unfavorable outcome. Overall, this case underscores the complexity of mixed cryoglobulinemia presentations and the challenges of managing severe cases with multi-organ involvement.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Journal, IO biomarker:  Immune myocarditis induced by sintilimab therapy: A case report. (Pubmed Central) -  Jul 15, 2024   
    After receiving hormonal shock therapy, Ctn I, CK, CK-MB and other cardiac enzyme-related markers improved significantly, and electrocardiogram test returned to normal, and the patient recovered during hospitalization without any major adverse cardiac events. Furthermore, the present study reviewed the mechanism of immune myocarditis induced by ICI therapy, with the aim of providing a clinical foundation for the prevention and diagnosis of cardiovascular adverse events in ICI therapy.
  • ||||||||||  Epkinly (epcoritamab-bysp) / Genmab, AbbVie
    Journal, IO biomarker:  Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas. (Pubmed Central) -  Jul 15, 2024   
    P1/2
    Single-cell immune profiling of tumor biopsies obtained following one cycle of therapy revealed substantial clonal expansion of cytotoxic CD4+ and CD8+ T-cells in patients achieving CR, and an expansion of follicular helper and regulatory CD4+ T-cells in patients whose disease progressed. These results identify distinct tumor-resident T-cell profiles associated with response or resistance to BsAb therapy.
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Virus specific T cells:  Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma. (Pubmed Central) -  Jul 15, 2024   
    Seven CPI-refractory metastatic MCC patients received CD4 and CD8 T cells transduced with TCR MCC1 (T TCR-MCC1 ) preceded either by lymphodepleting chemotherapy or an HLA-upregulating regimen (single-fraction radiation therapy (SFRT) or systemic interferon gamma (IFN?)) with concurrent avelumab...Indeed, supplying a strong co-stimulatory signal via a CD200R-CD28 switch receptor allows T TCR-MCC1 cells to control HLA-downregulated MCC cells in a xenograft mouse model, upregulating HLA expression. Our results demonstrate the potential of TCR gene therapy for metastatic MCC and propose a next strategy for overcoming epigenetic downregulation of HLA in MCC.
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Enrollment closed, Combination therapy:  TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na (clinicaltrials.gov) -  Jul 15, 2024   
    P2,  N=108, Active, not recruiting, 
    Active, not recruiting --> Recruiting | N=57 --> 83 | Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Dec 2023 --> Aug 2026 Recruiting --> Active, not recruiting
  • ||||||||||  Journal:  Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development. (Pubmed Central) -  Jul 14, 2024   
    Currently, there are 12 ongoing clinical trials exploring potential treatments such as leflunomide, low-dose IL-2, rituximab, abatacept, secukinumab, Janus kinase inhibitors, and selective inhibitors like SPI-62 and ABBV 154...The development of internationally accepted definitions for remission and relapse is urgently needed. Early referral strategies to specialist settings would improve disease stratification and personalized treatment.
  • ||||||||||  Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
    Retrospective data, Journal:  Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy. (Pubmed Central) -  Jul 14, 2024   
    SSc was effectively and safely treated with low-dose RTX quarterly. RCTs are warranted to validate the advantage of continuous B cell depletion by quarterly low-dose RTX administration compared to other treatment intervals.
  • ||||||||||  ubenimex (DFP-14323) - Delta / Fly Pharma
    Biomarker, Journal:  Leukotriene B4: A Potential Mediator and Biomarker for Cardiac Allograft Vasculopathy. (Pubmed Central) -  Jul 13, 2024   
    Although Lf was not able to increase the expression of autophagy-inducing genes, it may be able to induce autophagy through protein interaction by activating or inhibiting proteins related to autophagy regulation. This study provides key evidence supporting the role of the inflammatory cytokine LTB4 as an important mediator of CAV development
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
    Review, Journal:  Cardiotoxicity in Acute Myeloid Leukemia in Adults: A Scoping Study. (Pubmed Central) -  Jul 13, 2024   
    It is understandable that being familiar with all the treatment options available and every potential adverse effect is impossible. However, hematologists and, in general, physicians must try to be updated with the most recent information released to improve the quality of life of their patients and minimize the risk of additional complications.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development. (Pubmed Central) -  Jul 13, 2024   
    This review highlights the mechanism of action of ADCs, their application in mono- and combination therapies, primary mechanisms of resistance, and future perspectives for their clinical use in UC treatment. ADCs have proven to be an increasingly vital component of the therapeutic landscape for urothelial carcinoma, filling a gap in the treatment of this progressive disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Review, Journal, Metastases:  Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions. (Pubmed Central) -  Jul 13, 2024   
    We further discuss newer novel treatment options in the second and subsequent lines of treatment on progression, like immunotherapy in combination with other agents, including fibroblast growth factors receptor inhibitors, human epidermal growth factor inhibitors, antibody-drug conjugates, tyrosine kinase inhibitors, and novel antibodies. Finally, we discuss the integration of these novel therapies into current clinical practice amidst the rapidly evolving landscape of advanced bladder cancer treatment, aiming to enhance patient outcomes.
  • ||||||||||  Review, Journal:  Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts. (Pubmed Central) -  Jul 13, 2024   
    Therefore, systemic treatment for HCC is entering a new phase for all disease stages. The objective of this review is to organize the current position of systemic therapy for each HCC stage and discuss the development of new treatment methods and strategies, with a focus on regimens incorporating immune checkpoint inhibitors, along with future prospects.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer. (Pubmed Central) -  Jul 13, 2024   
    Lastly, for the remaining ~50% of patients who are fit and whose tumors have no or low PD-L1 expression (TPS of 0-49%) and no sensitizing EGFR/ALK aberrations, platinum-containing chemotherapy with the addition of a PD-1/L1 inhibitor alone or in combination of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor improves PFS and OS compared to chemotherapy alone. The objectives of this review are to summarize the current data and perspectives on first-line systemic treatment in patients with unresectable NSCLC and propose a practical algorithm for implementing precision biomarker testing at diagnosis.